Introduction
Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.

Aim
The VEBIS primary care network estimated influenza VE in Europe using a multicentre test‐negative study.

Methods
Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.

Results
We included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95%?CI: 44–59). By year of age, VE was 27% (95%?CI: ?2 to 47) at 44 years with peaks at 72% (95%?CI: 52–84) and 54% (95%?CI: 41–64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95%?CI: 24–54) and ?11% (95%?CI: ?69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95%?CI: 20–48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95%?CI: 1–62). All-age VE against B/Victoria was 83% (95%?CI: 65–94), ranging between 70 and 92% by age group.

Discussion
The 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.